Clinical use of cardiovascular risk score

Introduction: The American Heart Association has outlined strategic impact goals designed to improve the cardiovascular health of Americans by 20% by the year 2020 including improvements in lifestyle and behavior.

Hypothesis: We assessed the hypothesis that sharing with patients a 7-protein cardiovascular risk score would motivate them to better adhere to cardiovascular risk reduction measures.

Methods: The 7-protein risk score (SomaScan® CVD Secondary Risk Panel, SomaLogic) provides % risk by year for experiencing a cardiovascular event up to 5 years. Patients with stable coronary heart disease received a baseline lifestyle and behavior survey, chart abstraction, and blood draw for the 7-protein risk score. Results were shared with the patient by their physician. One month after receiving the panel results, patients were surveyed on the overall impact of the panel on health, lifestyle, and medication changes.

Results: Among the 198 enrolled patients, 25% had ≥ 20% predicted risk of a cardiovascular event in 5 years. Of the 131 patients with follow-up survey results to date, higher risk patients reported higher rates of desirable lifestyle changes, including healthier diet (Figure 4). Lower risk patients stated they would maintain their lifestyle to remain healthy.

Conclusions: Patients presented with their personal 7-protein cardiovascular risk score were motivated to improve their lifestyle and adherence to medications. The additional motivation from the test results, if sustained long-term, may translate into improved outcomes in patients with coronary heart disease.


Share with colleagues

More posters

PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points

The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.

Learn more

PosterStatin signature: using proteomics to detect pharmacological fingerprints

Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).

Learn more

PosterUsing a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease

Improvement in hepaKc inflammaKon, NAFLD acKvity score and fibrosis were associated with improved proteomic CV risk scores regardless of treatment provided.

Learn more

Explore posters in our interactive viewer